GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Allen, D.; Backeljauw, P.; Bidlingmaier, M.; Biller, B.; Boguszewski, M.; Burman, P.; Butler, G.; Chihara, K.; Christiansen, J.; Cianfarani, S.; Clayton, P.; Clemmons, D.; Cohen, P.; Darendeliler, Fatma; Deal, C.; Dunger, D.; Erfurth, E.; Fuqua, J.; Grimberg, A.; Haymond, M.; Higham, C.; Ho, K.; Hoffman, A.; Hokken-Koelega, A.; Johannsson, G.; Juul, A.; Kopchick, J.; Lee, P.; Pollak, M.; Radovick, S.; Robison, L.; Rosenfeld, R.; Ross, R.; Savendahl, L.; Saenger, P.; Sorensen, H.; Stochholm, K.; Strasburger, C.; Swerdlow, A.; Thorner, M.

doi:10.1530/eje-15-0873

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Atıf İçin Kopyala

Allen D. B., Backeljauw P., Bidlingmaier M., Biller B. M. K., Boguszewski M., Burman P., ...Daha Fazla

EUROPEAN JOURNAL OF ENDOCRINOLOGY, cilt.174, sa.2, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 174 Sayı: 2
Basım Tarihi: 2016
Doi Numarası: 10.1530/eje-15-0873
Dergi Adı: EUROPEAN JOURNAL OF ENDOCRINOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.